Project Grant R01AI200342
Award Date 8/10/26
Completion Date 7/31/31
Dollars Obligated $795K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $201,875 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate a novel family of alpha-helical peptides that regulate nitrogen metabolism and virulence in pathogenic Enterobacteria, particularly enteroaggregative E. coli (EAEC). The research employs human intestinal organoids alongside infection and fitness mouse models to elucidate the regulatory...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,990 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and target bacterial and genetic superspreaders of antimicrobial resistance genes in hospital ecosystems. The research investigates mechanisms of antibiotic resistance gene transfer within hospital environments, particularly focusing on carbapenemase resistance spreading through wastewater and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Virginia $253,445 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanistic insights into enteropathogen-mediated MUC3/4 signaling disruption and intestinal inflammation onset. The research uses human intestinal organoids to examine novel mechanisms triggering intestinal inflammation and mucosal...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $808,607 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize AI-designed antimicrobial peptides targeting ESKAPE pathogens. The project integrates artificial intelligence, machine learning, chemical approaches, and computational tools to develop peptide-based therapeutics against multidrug-resistant bacteria including...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $713,396 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular mechanisms of protective lung resident memory T cells. The project examines how lung tissue-resident memory CD8+ T cells provide broad-spectrum protection against influenza infection, including heterologous protection against variant strains. The research focuses on a...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $236,538 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize biofilm formation mechanisms in Shigella flexneri, the causative agent of bacillary dysentery. The research will identify structural determinants supporting ICSA-mediated bile-salt-dependent biofilm formation and evaluate the role of the ICSA bacterial adaptor protein in both...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $117,530 on December 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a project grant investigating the molecular mechanisms by which the human complement inhibitor C4B-binding protein protects Neisseria gonorrhoeae from neutrophil-mediated killing during infection. The research defines how C4B-binding protein interrupts interactions between gonococcal opacity...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...